Genetically modified salmonella strains for evading host immune response
Genetically modified Salmonella strains with specific gene deletions and regulated lysis vectors overcome immune response misdirection, enabling effective antigen and therapeutic delivery to tumors, enhancing immune protection against pathogens and cancers.
Patent Information
- Application Number
- PCT/US2025/047380
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-10-18
- Filing Date
- 2025-09-22
- Publication Date
- 2026-04-23
AI Technical Summary
Existing genetically modified Salmonella strains induce strong innate and adaptive immune responses, misdirecting the host's immune response and disrupting the elicitation of protective immunity against targeted pathogens and cancers, limiting their use as a universal vaccine and therapeutic delivery platform.
Genetically modified Salmonella strains with deletions in specific genes (yfgL, yiaD, STM1540, STM1940, slyB, fepA, iroN, cirA, ydcW, yfiO) and mutations in pmi, murA, asdA, and arabinose-regulated lysis vectors, combined with recombinant polynucleotides encoding TRAIL and DNA nuclear targeting sequences, to reduce immunogenicity and enable regulated delayed lysis for antigen and therapeutic delivery.
The modified strains effectively evade host immune responses, colonize tumor tissues, and deliver protective antigens and therapeutics, providing long-lasting protection and targeted immune responses against pathogens and cancers without persistence in the host.